BridgeMD
Use of half the iodinated contrast medium for monitoring thoracic neoplasms using spectral CT: Randomized, crossover, non-inferiority clinical trial
EU CTIS ID: 2025-524901-33-00
What this study is testing
To qualitatively and quantitatively compare two iodinated contrast administration protocols in oncologic staging CT studies of thoracic tumors, one using half the contrast dose and the other the standard dose, by analyzing the following parameters: vascular attenuation and signal-to-noise ratio (pulmonary arteries and aorta), hepatic attenuation and signal-to-noise ratio, and subjective assessment of overall image quality and image noise.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- All consecutive patients older than 18 years referred to our department for contrast-enhanced thoracoabdominopelvic CT for staging of a primary pulmonary or pleural malignancy, either at initial diagnosis or during disease follow-up, will be included.
You likely can't join if
- Patients with known allergy or hypersensitivity to iodinated contrast media and/or any of its excipients.
- Renal insufficiency with an estimated glomerular filtration rate (eGFR) <30 mL/min.
- Patient refusal to participate in the study or inability to provide informed consent.
- Incomplete administration of contrast medium according to the assigned protocol due to issues with venous access, injector malfunction, central venous access, or related technical problems.
- Body weight <50 kg or >90 kg.
- Inability to perform the examination on the spectral CT scanner due to equipment malfunction, unavailability, or related technical issues.
See the full eligibility criteria
- All consecutive patients older than 18 years referred to our department for contrast-enhanced thoracoabdominopelvic CT for staging of a primary pulmonary or pleural malignancy, either at initial diagnosis or during disease follow-up, will be included.
- Patients with known allergy or hypersensitivity to iodinated contrast media and/or any of its excipients.
- Renal insufficiency with an estimated glomerular filtration rate (eGFR) <30 mL/min.
- Patient refusal to participate in the study or inability to provide informed consent.
- Incomplete administration of contrast medium according to the assigned protocol due to issues with venous access, injector malfunction, central venous access, or related technical problems.
- Body weight <50 kg or >90 kg.
- Inability to perform the examination on the spectral CT scanner due to equipment malfunction, unavailability, or related technical issues.
- Pregnant women or women with a possibility of being pregnant.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.